168 related articles for article (PubMed ID: 29437768)
1. FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.
Shah A; Bloomquist E; Tang S; Fu W; Bi Y; Liu Q; Yu J; Zhao P; Palmby TR; Goldberg KB; Chang CJG; Patel P; Alebachew E; Tilley A; Pierce WF; Ibrahim A; Blumenthal GM; Sridhara R; Beaver JA; Pazdur R
Clin Cancer Res; 2018 Jul; 24(13):2999-3004. PubMed ID: 29437768
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2.
Verma S; O'Shaughnessy J; Burris HA; Campone M; Alba E; Chandiwana D; Dalal AA; Sutradhar S; Monaco M; Janni W
Breast Cancer Res Treat; 2018 Aug; 170(3):535-545. PubMed ID: 29654415
[TBL] [Abstract][Full Text] [Related]
3. Ribociclib plus Endocrine Therapy in Early Breast Cancer.
Slamon D; Lipatov O; Nowecki Z; McAndrew N; Kukielka-Budny B; Stroyakovskiy D; Yardley DA; Huang CS; Fasching PA; Crown J; Bardia A; Chia S; Im SA; Ruiz-Borrego M; Loi S; Xu B; Hurvitz S; Barrios C; Untch M; Moroose R; Visco F; Afenjar K; Fresco R; Severin I; Ji Y; Ghaznawi F; Li Z; Zarate JP; Chakravartty A; Taran T; Hortobagyi G
N Engl J Med; 2024 Mar; 390(12):1080-1091. PubMed ID: 38507751
[TBL] [Abstract][Full Text] [Related]
4. FDA Approval Summary: Ribociclib Indicated for Male Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.
Gao JJ; Osgood CL; Feng Z; Bloomquist EW; Tang S; Chang CJG; Ricks TK; Hou SC; Pierce WF; Rivera DR; Pazdur R; Kluetz PG; Amiri-Kordestani L
Clin Cancer Res; 2023 Dec; 29(24):5008-5011. PubMed ID: 37594723
[TBL] [Abstract][Full Text] [Related]
5. Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
De Laurentiis M; Borstnar S; Campone M; Warner E; Bofill JS; Jacot W; Dent S; Martin M; Ring A; Cottu P; Lu J; Ciruelos E; Azim HA; Chatterjee S; Zhou K; Wu J; Menon-Singh L; Zamagni C
Breast Cancer Res Treat; 2021 Oct; 189(3):689-699. PubMed ID: 34414532
[TBL] [Abstract][Full Text] [Related]
6. The effects of low HER2 expression on survival in patients with metastatic breast cancer treated with CDK 4/6 inhibitors: a multicenter retrospective study.
Guliyev M; Şen GA; Gültürk İ; Majidova N; Akdağ G; Ahadzade A; Turna H; Demirci NS
Breast Cancer Res Treat; 2024 Jun; 205(3):633-640. PubMed ID: 38526689
[TBL] [Abstract][Full Text] [Related]
7. Ribociclib-Induced Cutaneous Adverse Events in Metastatic HR+/HER2- Breast Cancer: Incidence, Multidisciplinary Management, and Prognostic Implication.
Borroni RG; Bartolini M; Gaudio M; Jacobs F; Benvenuti C; Gerosa R; Tiberio P; Manara SAAM; Solferino A; Santoro A; De Sanctis R
Oncologist; 2024 Jun; 29(6):484-492. PubMed ID: 38242689
[TBL] [Abstract][Full Text] [Related]
8. Intrinsic Subtype and Overall Survival of Patients with Advanced HR+/HER2- Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7.
Prat A; Solovieff N; André F; O'Shaughnessy J; Cameron DA; Janni W; Sonke GS; Yap YS; Yardley DA; Partridge AH; Thuerigen A; Zarate JP; Lteif A; Su F; Carey LA
Clin Cancer Res; 2024 Feb; 30(4):793-802. PubMed ID: 37939142
[TBL] [Abstract][Full Text] [Related]
9. Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast Cancer.
Ji Y; Schiller H; Yang S; Quinlan M; Darstein C; Huth F; Winter S; Chakraborty A
Clin Pharmacokinet; 2024 Feb; 63(2):155-170. PubMed ID: 38244190
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of ribociclib plus letrozole versus palbociclib plus letrozole in the United Kingdom.
Suri G; Chandiwana D; Lee A; Mistry R
J Health Econ Outcomes Res; 2019; 6(2):20-31. PubMed ID: 32685577
[TBL] [Abstract][Full Text] [Related]
11. Liver toxicity with ribociclib in a patient with metastatic hormone receptor positive postmenopausal breast cancer.
Sozer Karadagli S; Gursoy P
J Oncol Pharm Pract; 2024 Mar; 30(2):404-407. PubMed ID: 37899576
[TBL] [Abstract][Full Text] [Related]
12. Final results of RIGHT Choice: Ribociclib plus endocrine therapy vs combination chemotherapy in premenopausal women with clinically aggressive HR+/HER2- advanced breast cancer.
Lu YS; Bin Mohd Mahidin EI; Azim H; Eralp Y; Yap YS; Im SA; Rihani J; Gokmen E; El Bastawisy A; Karadurmus N; Lim YN; Lim CS; Duc LT; Chung WP; Babu KG; Penkov K; Bowles J; Alfaro TD; Wu J; Gao M; Slimane K; El Saghir NS
J Clin Oncol; 2024 May; ():JCO2400144. PubMed ID: 38771995
[TBL] [Abstract][Full Text] [Related]
13. Real-World Evidence of Ribociclib Plus Aromatase Inhibitors as First-Line Treatment in Advanced Breast Cancer: The BrasiLEEira Study.
Suzuki DA; Morelle AM; de Brito ML; Paes FR; Mattar A; Leal JHS; Simon SD; Lima EMA; Werutsky G; Piotto GHM; Bines J; Damiani LP; Macedo A; Campos L; Buehler AM
JCO Glob Oncol; 2024 Apr; 10():e2300484. PubMed ID: 38603658
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular complications of ribociclib in breast cancer patients.
Fiste O; Mavrothalassitis E; Apostolidou K; Trika C; Liontos M; Koutsoukos K; Kaparelou M; Dimitrakakis C; Gavriatopoulou M; Dimopoulos MA; Zagouri F
Crit Rev Oncol Hematol; 2024 Apr; 196():104296. PubMed ID: 38395242
[TBL] [Abstract][Full Text] [Related]
15. An integrated assessment of the ADME properties of the CDK4/6 Inhibitor ribociclib utilizing preclinical in vitro, in vivo, and human ADME data.
James AD; Schiller H; Marvalin C; Jin Y; Borell H; Roffel AF; Glaenzel U; Ji Y; Camenisch G
Pharmacol Res Perspect; 2020 Jun; 8(3):e00599. PubMed ID: 32524755
[TBL] [Abstract][Full Text] [Related]
16. Ribociclib may potentiate rosuvastatin effect in causing late onset rhabdomyolysis.
Teo SW; Hayes T; Gome J
BMJ Case Rep; 2023 Sep; 16(9):. PubMed ID: 37696610
[TBL] [Abstract][Full Text] [Related]
17. Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy.
Pascual T; Fernandez-Martinez A; Agrawal Y; Pfefferle AD; Chic N; Brasó-Maristany F; Gonzàlez-Farré B; Paré L; Villacampa G; Saura C; Hernando C; Muñoz M; Galván P; Gonzàlez-Farré X; Oliveira M; Gil-Gil M; Ciruelos E; Villagrasa P; Gavilá J; Prat A; Perou CM
NPJ Breast Cancer; 2024 Mar; 10(1):20. PubMed ID: 38448600
[TBL] [Abstract][Full Text] [Related]
18. Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Burris HA
Expert Rev Anticancer Ther; 2018 Mar; 18(3):201-213. PubMed ID: 29457921
[TBL] [Abstract][Full Text] [Related]
19. Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials.
Ramos-Esquivel A; Hernández-Steller H; Savard MF; Landaverde DU
Breast Cancer; 2018 Jul; 25(4):479-488. PubMed ID: 29470723
[TBL] [Abstract][Full Text] [Related]
20. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring
Odogwu L; Mathieu L; Blumenthal G; Larkins E; Goldberg KB; Griffin N; Bijwaard K; Lee EY; Philip R; Jiang X; Rodriguez L; McKee AE; Keegan P; Pazdur R
Oncologist; 2018 Jun; 23(6):740-745. PubMed ID: 29438093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
